Express Scripts adds Aimovig, Emgality to new value-based migraine program; excludes Ajovy

Express Scripts Holding Co. (NASDAQ:ESRX) will include two of three FDA approved migraine prevention drugs in its value-based program for migraine, which it unveiled Oct. 17. The PBM gave the nod to Aimovig erenumab-aooe from Amgen Inc. (NASDAQ:AMGN) and Novartis AG (NYSE:NVS; SIX:NOVN) and Emgality galcanezumab-gnlm from Eli Lilly and Co. (NYSE:LLY), but excluded Ajovy fremanezumab-vfrm from Teva Pharmaceutical

Read the full 591 word article

User Sign In